Abstract: TH-PO832
The Effects of Brazilian Green Propolis Extract on Inflammation in CKD on Peritoneal Dialysis (PD): A Randomized Double-Blind Controlled Clinical Trial
Session Information
- Health Maintenance, Nutrition, Metabolism
November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Health Maintenance‚ Nutrition‚ and Metabolism
- 1400 Health Maintenance‚ Nutrition‚ and Metabolism
Authors
- Mafra, Denise, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Baptista, Beatriz Germer, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Cardozo, Ludmila Fmf, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Ribeiro-Alves, Marcelo, Fundacao Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
- Ribeiro, Marcia Maria, Universidade Federal do Rio de Janeiro Centro de Ciencias da Saude, Rio de Janeiro, RJ, Brazil
- Fanton, Susane, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Alvarenga, Livia De almeida, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- de Paiva, Bruna Regis, Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil
- Shiels, Paul G., University of Glasgow, Glasgow, Glasgow, United Kingdom
- Berretta, Andresa, Apis Flora, São Paulo, Brazil
Group or Team Name
- Renal Nutrition - UFF
Background
Chronic kidney disease (CKD) patients on dialysis display a low-grade systemic inflammatory burden. Nutritional interventions designed to activate the cytoprotective nuclear factor Nrf2, and inhibit nuclear NF-κB have been proposed to mitigate this burden. Several bioactive compounds have been investigated to achieve this, including propolis, a resin produced by Apis mellifera bees. The aim of the study was to evaluate the effects of propolis supplementation on inflammatory markers in patients with CKD on PD.
Methods
CKD patients were randomized into two groups: propolis (4 capsules of 100 mg/day containing concentrated and standardized dry EPP-AF® Brazilian green propolis extract) or placebo for two months. The plasma levels of TNF-α and IL-6 were evaluated by ELISA. Quantitative real-time PCR analyses were performed to evaluate the expression of Nrf2 and NF-κB in peripheral blood mononuclear cells. Plasma malondialdehyde (MDA) levels and routine biochemical markers were analyzed. Carotid Intima-Media Thickness (CIMT) was measured with a doppler ultrasonography device.
Results
A total of 19 patients completed the study, ten patients in the propolis group (54 ± 1.0 years, five men, 7.2 ± 5.1 months on PD) and nine in the placebo group (47.5 ± 15.2 years, three men, 10.8 ± 24.3 months on PD). There were no differences in baseline values in both groups (Table 1). The plasma levels of TNF-α reduced significantly (p=0.02), and mRNA expression of Nrf2 showed a trend to increase (p=0.07) after propolis supplementation.
Conclusion
EPP-AF® Green Propolis extract (400 mg/day) supplementation for two months mitigated inflammation by reducing TNF-α levels in CKD patients on PD.
Inflammation markers, biochemical parameters, and CIMT values in placebo and propolis groups at the baseline.
| Inflammation markers | Overall | Placebo Group | Propolis Group | p-values |
| Ultrasound (mm) | 0.7 (0.2) | 0.6 (0.2) | 0.7 (0.1) | 0.892 |
| MDA (nmol/mL) | 0.80 (0.6) | 0.87 (1.6) | 0.64 (0.5) | 0.131 |
| TNF-α (pg/mL) | 48.1 (15.9) | 53.7 (17.5) | 47.5 (11.8) | 0.820 |
| CRP (mg/mL) | 7.9 (9.7) | 5.8 (10) | 8.3 (9.3) | 0.594 |
| NF-κB (a.u) | 0.87 (0.6) | 0.95 (0.5) | 0.79 (0.6) | 0.518 |
| Nrf2 (a.u.) | 1.04 (0.6) | 1.05 (0.3) | 0.85 (0.5) | 0.351 |
Funding
- Government Support – Non-U.S.